MonzrMAl MalkiMD

Hematology • Duarte, CA

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Associate Professor, Hematology and Hematopoietic Cell Transplantation

Join to view full profile

Dr. Al Malki is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Al Malki's full profile

Already have an account?

Office
Hematology and HCT
1500 East Duarte Road
Duarte, CA 91010
Phone+1 626-256-4673

Fax+1 626-389-3058
Is this information wrong?

Summary

Dr. Monzr Al Malki is a hematologist in Duarte, CA and is affiliated with City of Hope's Helford Clinical Research Hospital. He received his medical degree from Damascus University Faculty of Medicine and has been in practice 14 years. He also speaks multiple languages, including Arabic and Spanish. He specializes in hematologic oncology and myeloproliferative disorder hematology-oncology and is experienced in aplastic anemia, hematopoietic stem cell transplantation, acute myeloid leukemia, hodgkin's lymphoma, and multiple myeloma.

Education & Training

Roger Williams Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Damascus University Faculty of MedicineClass of 2003
Cleveland Clinic FoundationResidency, Internal Medicine

Certifications & Licensure

CA State Medical License 2014 - 2025
MA State Medical License 2008 - 2016
RI State Medical License 2008 - 2016
OH State Medical License 2005 - 2008

Clinical Trials

Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease Start of enrollment: 2016 Aug 01
Completed
Phase 2
Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma Start of enrollment: 2015 Jan 20
Active, not recruiting
Phase 2
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
No longer available
BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma Start of enrollment: 2016 Dec 02
Terminated
Phase 2
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis Start of enrollment: 2017 May 24
Recruiting
Phase 1
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant Start of enrollment: 2017 May 30
Completed
Phase 2
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome Start of enrollment: 2018 Jul 06
Recruiting
Phase 1
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702) Start of enrollment: 2019 Jun 14
Active, not recruiting
Not Applicable
TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) Start of enrollment: 2019 Jun 25
Completed
Phase 3
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia Start of enrollment: 2020 Feb 07
Recruiting
Phase 2
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT Start of enrollment: 2020 Feb 20
Active, not recruiting
Phase 1, Phase 2
SARS-CoV-2 Donor-Recipient Immunity Transfer Start of enrollment: 2020 Sep 23
Completed
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Start of enrollment: 2021 Sep 30
Recruiting
Phase 2
Study of GDX012 in Patients With MRD Positive AML Start of enrollment: 2021 Aug 13
Terminated
Phase 1
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies Start of enrollment: 2021 Jun 16
Terminated
Phase 2
Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the National Cord Blood Program (NCBP) for Unrelated Transplantation Start of enrollment: 2012 Feb 01
Recruiting
Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia Start of enrollment: 2014 Feb 10
Active, not recruiting
Phase 2
Magrolimab in Combination With Azacitidine After Allogeneic HCTin Treating Patients With High-Risk AML or MDS Start of enrollment: 2024 Jun 09
Suspended
Phase 1
Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies Start of enrollment: 2023 Jun 16
Recruiting
Phase 1
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants Start of enrollment: 2022 Nov 23
Recruiting
Phase 2
A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation Start of enrollment: 2022 Nov 01
Recruiting
Phase 1
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2023 Jul 11
Recruiting
Phase 1, Phase 2
Passive Music Intervention for the Reduction of Anxiety in Patients Undergoing Bone Marrow Aspiration and/or Biopsy Start of enrollment: 2024 Apr 18
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

1 citations
HIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation.
Al Malki, M. M., Jana K Dickter, Ahmed Aribi, Angelo A Cardoso, Sara Gianella, Ketevan Gendzekhadze, Shirley Li, Ye Feng, Antoine Chaillon, Gregory M Laird, Diana L Br...> ;The New England Journal of Medicine. 2024 Feb 15
Lack of RBC transfusion independence by Day 30 following allogeneic hematopoietic stem cell transplant strongly predicts inferior survival and high non-relapse mortali...
Al Malki, M. M., Al Malki, M. M., Al Malki, M. M., Al Malki, M. M., Al Malki, M. M., Shan Yuan, Dongyun Yang, Ryotaro Nakamura, Monzr M Al Malki, Amandeep Salhotra, Mi...> ;Transfusion. 2024 Feb 1
Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Pos...
Elmariah, H., Otoukesh, S., Kumar, A., Ali, H., Arslan, S., Shouse, G., Pourhassan, H., Nishihori, T., Faramand, R., Mishra, A., Khimani, F., Fernandez, H., Lazaryan, ...> ;Transplantation and Cellular Therapy. 2024 Feb 1
Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplant...
Flavia Chiuppesi, Sandra Ortega-Francisco, Miguel-Angel Gutierrez, Jing Li, Minh Ly, Katelyn Faircloth, Jada Mack-Onyeike, Corinna La Rosa, Sandra Thomas, Qiao Zhou, J...> ;Vaccines. 2023 Sep 15
2 citations
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Re...
Naval G Daver, Paresh Vyas, Suman Kambhampati, Monzr M Al Malki, Richard A Larson, Adam S Asch, Gabriel Mannis, Wanxing Chai-Ho, Tiffany N Tanaka, Terrence J Bradley, ...> ;Journal of Clinical Oncology. 2023 Nov 1
Specificity of HLA monoclonal antibodies and their use to determine HLA expression on lymphocytes and peripheral blood stem cells.
Benjamin Peton, Michiko Taniguchi, Massimo Mangiola, Monzr M Al Malki, Ketevan Gendzekhadze> ;HLA. 2024 Jan 1
-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens.
Ahmed Aribi, Amandeep Salhotra, Michelle Afkhami, Anamaria Munteanu, Haris Ali, Ibrahim Aldoss, Salman Otoukesh, Monzr M Al Malki, Karamjeet S Sandhu, Paul Koller, Shu...> ;Leukemia & Lymphoma. 2023 Aug 3
Editorial: Total marrow irradiation.
Susanta Kumar Hui, Guy Storme, Jeffrey Wong, Cynthia Aristei, Monzr M Al Malki, Bulent Aydogan> ;Frontiers in Oncology. 2023 Jan 1
42 citations
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.
Javier Bolaños-Meade, Mehdi Hamadani, Juan Wu, Monzr M Al Malki, Michael J Martens, Lyndsey Runaas, Hany Elmariah, Andrew R Rezvani, Mahasweta Gooptu, Karilyn T Larkin...> ;The New England Journal of Medicine. 2023 Jun 22
Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation UsingY-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan i...
Matthew Mei, Joycelynne Palmer, Nicole Ni-Chun Tsai, Jennifer Simpson, James O'Hearn, Anthony Stein, Stephen Forman, Ricardo Spielberger, Ji-Lian Cai, Myo Htut, Ryotar...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Sep 1
1 citations
Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Ver...
Janny M Yao, Salman Otoukesh, Hanna Kim, Dongyun Yang, Sally Mokhtari, Yazeed Samara, Amanda Blackmon, Shukaib Arslan, Vaibhav Agrawal, Hoda Pourhassan, Idoroenyi Aman...> ;Transplantation and Cellular Therapy. 2023 Aug 1
Haploidentical hematopoietic cell transplant recipient presents with late-onset Epstein Barr virus-associated posttransplant lymphoproliferative disorder.
Adam Braun, Lawrence Liu, Monzr M Al Malki, Pamela S Becker> ;Ejhaem. 2023 Aug 1
Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience.
Al Malki, M. M., Idoroenyi Amanam, Janny Yao, Alfredo Puing, Ni-Chun Tsai, Diana Samuels, Dat Ngo, Stephanie Ho, Haris Ali, Ahmed Aribi, Shukaib Arslan, Andrew Artz, M...> ;Cancer Medicine. 2023 May 1
2 citations
The impact of SARS-CoV2 vaccines on the incidence of graft versus host disease in allogeneic hematopoietic stem cell transplant recipients: a single-center retrospecti...
Dat Ngo, Jason Chen, Jose Tinajero, Ahmed Aribi, Shukaib Arslan, Guido Marcucci, Ryotaro Nakamura, Monzr M Al Malki, Stephen J Forman, Sanjeet Dadwal, Haris Ali> ;Stem Cell Research & Therapy. 2023 Apr 18
Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration.
Tania Jain, Hua-Ling Tsai, Hany Elmariah, Pankit Vachhani, Theodoros Karantanos, Sarah Wall, Lukasz Gondek, Asad Bashey, Alla Keyzner, Roni Tamari, Michael Grunwald, S...> ;Research Square. 2023 Mar 21
4 citations
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Phila...
Ibrahim Aldoss, Michelle Afkhami, Dongyun Yang, Zhaohui Gu, Sally Mokhtari, Shilpa Shahani, Hoda Pourhassan, Vaibhav Agrawal, Paul Koller, Shukaib Arslan, Vanina Tomas...> ;American Journal of Hematology. 2023 Jun 1
2 citations
Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study.
Corinna La Rosa, Flavia Chiuppesi, Yoonsuh Park, Qiao Zhou, Dongyun Yang, Ketevan Gendzekhadze, Minh Ly, Jing Li, Teodora Kaltcheva, Sandra Ortega Francisco, Miguel-An...> ;Frontiers in Immunology. 2023 Jan 1
9 citations
Effective treatment of low-risk acute GVHD with itacitinib monotherapy.
Kapoor, U., Aaron Etra, Alexandra Capellini, Amin Alousi, Monzr M Al Malki, Hannah Choe, Zachariah DeFilipp, William J Hogan, Carrie L Kitko, Francis Ayuk, Janna Baez,...> ;Blood. 2023 Feb 2
1 citations
Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab.
Vaibhav Agrawal, Hoda Pourhassan, Ni-Chun Tsai, Dat Ngo, Paul Koller, Monzr M Al Malki, Amandeep Salhotra, Haris Ali, Ahmed Aribi, Karamjeet S Sandhu, Shukaib Arslan, ...> ;Transplantation and Cellular Therapy. 2023 May 1
Association of pre-transplant vancomycin resistant enterococcus colonization status on long-term outcomes of allogeneic-hematopoietic cell transplantation.
Amandeep Salhotra, Karamjeet S Sandhu, Dongyun Yang, Sally Mokhtari, James O'Hearn, Bernard Tegtmeier, Monzr M Al Malki, Justine Abella, Akemi Meguro, Jana Dickter, Sw...> ;Bone Marrow Transplantation. 2023 Mar 1
2 citations
New strategies for mismatched unrelated donor (MMUD) hematopoietic cell transplant (HCT).
Shukaib Arslan, Monzr M Al Malki> ;Hematology. American Society of Hematology. Education Program. 2022 Dec 9
Total marrow irradiation reduces organ damage and enhances tissue repair with the potential to increase the targeted dose of bone marrow in both young and old mice.
Ji Eun Lim, Srideshikan Sargur Madabushi, Paresh Vishwasrao, Joo Y Song, Amr M H Abdelhamid, Hemendra Ghimire, V L Vanishree, Jatinder K Lamba, Savita Dandapani, Amand...> ;Frontiers in Oncology. 2022 Jan 1
11 citations
Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL.
Ibrahim Aldoss, Samer K Khaled, Xiuli Wang, Joycelynne Palmer, Yan Wang, Jamie R Wagner, Mary C Clark, Jennifer Simpson, Jinny Paul, Vibhuti Vyas, Sheng-Hsuan Chien, A...> ;Clinical Cancer Research. 2023 Feb 16
CT-505 Fractionated Total Body Irradiation and Fludarabine Based Conditioning Regimen With Post-Transplant Cyclophosphamide (PTCy) for Mismatched Related and Unrelated...
Desai A, Yang D, Blackmon A, Stein A, Marcucci G, Forman S, Nakamura R, Al-Malki M> ;Clinical lymphoma, myeloma & leukemia.
2 citations
Risk of Subsequent Malignant Neoplasms Following Hematopoietic Stem Cell Transplantation with Total Body Irradiation or Total Marrow Irradiation: Insights from Early F...
Colton Ladbury, Saro Armenian, Alysia Bosworth, Tianhui He, F Lennie Wong, Savita Dandapani, Chunhui Han, An Liu, Monzr Al Malki, Joseph Rosenthal, Anthony Stein, Jeff...> ;Transplantation and Cellular Therapy. 2022 Dec 1
Join now to see all

Abstracts/Posters

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
Monzr M. Al Malki, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Updated Analysis: Novel Machine-Learning-Based Sepsis Prediction Model for Patients Undergoing Hematopoietic Stem Cell Transplantation (Early Sepsis Prediction/Identif...
Monzr M. Al Malki, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplan...
Monzr M. Al Malki, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Downregulation of Mir-142 Promotes Leukemia Growth in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): A Possible Novel Therapeutic Target?
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018